Research programme: BIO5 Institute/Johnson and Johnson Consumer and Personal Products/Janssen Biotech

Drug Profile

Research programme: BIO5 Institute/Johnson and Johnson Consumer and Personal Products/Janssen Biotech

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator BIO5 Institute; Johnson & Johnson
  • Developer Johnson & Johnson
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Asthma

Most Recent Events

  • 11 Jun 2015 Early research in Asthma in USA (unspecified route)
  • 11 Jun 2015 BIO5 Institute and Johnson and Johnson Innovation agree to co-develop asthma therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top